This is my assumption but as the terms for milestone payments specifically call out first "commercial" sale I would anticipate that any sales from the patient access program would not trigger the milestone as they are not commercial in nature. These types of programs typically supply the drug for free in any case or are at least heavily subsidised.
- Forums
- ASX - By Stock
- NEU
- Ann: Trofinetide marketing application submitted in Europe
NEU
neuren pharmaceuticals limited
Add to My Watchlist
2.23%
!
$12.26

Ann: Trofinetide marketing application submitted in Europe, page-9
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$12.26 |
Change
-0.280(2.23%) |
Mkt cap ! $1.525B |
Open | High | Low | Value | Volume |
$12.45 | $12.45 | $11.88 | $6.952M | 570.0K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 231 | $12.26 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$12.32 | 1979 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 231 | 12.260 |
1 | 3000 | 12.250 |
2 | 3451 | 12.200 |
1 | 1579 | 12.190 |
3 | 3885 | 12.180 |
Price($) | Vol. | No. |
---|---|---|
12.320 | 1979 | 2 |
12.330 | 1885 | 2 |
12.340 | 1579 | 1 |
12.360 | 2001 | 1 |
12.370 | 1579 | 1 |
Last trade - 16.13pm 23/06/2025 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |